معرفی
Professor Fran Balkwill OBE, FMedSci, FRS serves as Professor of Cancer Biology and Director of Research at Barts Cancer Institute, where she leads the Centre of the Cell as Founder and Director. A Fellow of both the Academy of Medical Sciences and Royal Society, her work bridges fundamental cancer biology with clinical translation, focusing on inflammation-cancer interactions in ovarian malignancies.
Her research program centers on tumor microenvironment dynamics in ovarian cancer, utilizing human multi-cellular tissue culture models and mouse systems to investigate inflammatory cytokines' role in cancer promotion. Key focus areas include Targeting the Tumour Microenvironment, Cancer Immunity, and Cell Signalling pathways to develop biological therapies preventing relapse and improving survival outcomes.
Recent publications (2022-2024) reveal consistent emphasis on high-grade serous ovarian cancer models, immunotherapy combinations, and CAR T cell applications within complex tumor microenvironments. Her work demonstrates particular expertise in translating microenvironmental insights into therapeutic strategies that overcome treatment resistance.
Major scientific recognition includes:
- OBE for services to cancer research
- Election as Fellow of the Academy of Medical Sciences (FMedSci)
- Election as Fellow of the Royal Society (FRS)
She currently directs significant research funding including UKRI's £2.15M REMODEL grant (2022-2027) and Cancer Research UK awards totaling £3.58M (2017-2023), while supervising a multidisciplinary team investigating ovarian cancer biology. Additional leadership roles include Deputy Chair of CRUK's Clinical Research Committee and Chair of Prostate Cancer UK's Research Advisory Committee through 2025.
Her laboratory operates within Barts Cancer Institute's Centre of the Cell, developing innovative 3D human tissue culture platforms and mouse models to study tumor-immune interactions, with particular focus on translating microenvironmental discoveries into clinical applications for ovarian cancer patients.
